BIO-TECHNE CORP's ticker is TECH and the CUSIP is 09073M104. A total of 431 filers reported holding BIO-TECHNE CORP in Q4 2020. The put-call ratio across all filers is 1.11 and the average weighting 0.2%.
About BIO-TECHNE CORP
Bio-Techne Corp is a leading provider of innovative life science research tools and diagnostic solutions. The company is headquartered in Minneapolis, Minnesota, and has operations in over 50 countries worldwide. Bio-Techne's products and services are used by researchers and clinicians in a wide range of fields, including cancer research, stem cell research, and immunology.
Bio-Techne's success is due in large part to its commitment to innovation and customer service. The company invests heavily in research and development, and has a team of over 1,000 scientists working to develop new products and technologies. Bio-Techne also has a strong focus on customer service, with a dedicated team of technical support specialists available to assist customers with any questions or issues they may have.
In addition to its research tools and diagnostic solutions, Bio-Techne also has a growing portfolio of clinical diagnostic products. The company's Exosome Diagnostics subsidiary is a leader in the development of liquid biopsy tests for cancer diagnosis and monitoring.
Bio-Techne's leadership team is comprised of experienced executives with a track record of success in the life sciences industry. Charles Kummeth, the company's CEO, has been with Bio-Techne since 2013 and has overseen significant growth and expansion during his tenure.
Overall, Bio-Techne is a company with a strong reputation for innovation, customer service, and leadership in the life sciences industry. With a growing portfolio of products and services, the company is well-positioned for continued success in the years to come.
It's important to note that this information is for educational purposes only and has not been fact-checked. As with any investment, it's important to do your own research and consult with a financial advisor before making any investment decisions.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $5,917,372 | +221773.7% | 86,931 | +163.5% | 0.03% | +47.6% |
| Q4 2022 | $2,667 | -99.9% | 32,986 | +320.0% | 0.02% | +10.5% |
| Q3 2022 | $2,229,000 | -18.9% | 7,854 | +0.1% | 0.02% | -17.4% |
| Q2 2022 | $2,749,000 | -17.0% | 7,849 | +0.6% | 0.02% | -4.2% |
| Q1 2022 | $3,312,000 | -5.1% | 7,800 | -17.7% | 0.02% | -7.7% |
| Q4 2021 | $3,489,000 | -25.7% | 9,480 | +2.1% | 0.03% | -7.1% |
| Q3 2021 | $4,693,000 | -58.7% | 9,289 | -61.1% | 0.03% | -58.8% |
| Q2 2021 | $11,371,000 | +21.4% | 23,895 | +10.3% | 0.07% | +21.4% |
| Q1 2021 | $9,369,000 | -24.3% | 21,664 | -37.6% | 0.06% | -29.1% |
| Q4 2020 | $12,379,000 | +3.5% | 34,714 | -22.1% | 0.08% | -9.2% |
| Q3 2020 | $11,960,000 | +46.2% | 44,552 | +50.3% | 0.09% | +38.1% |
| Q2 2020 | $8,181,000 | +16.0% | 29,650 | -15.1% | 0.06% | -3.1% |
| Q1 2020 | $7,052,000 | +0.7% | 34,939 | +6.3% | 0.06% | +22.6% |
| Q4 2019 | $7,000,000 | +5.7% | 32,865 | +0.0% | 0.05% | +1.9% |
| Q3 2019 | $6,624,000 | +11.2% | 32,850 | +15.8% | 0.05% | +8.3% |
| Q2 2019 | $5,957,000 | -4.9% | 28,361 | -7.9% | 0.05% | -5.9% |
| Q1 2019 | $6,266,000 | +22.3% | 30,806 | -1.1% | 0.05% | +15.9% |
| Q4 2018 | $5,125,000 | -2.7% | 31,147 | +8.4% | 0.04% | +4.8% |
| Q3 2018 | $5,268,000 | +3.8% | 28,731 | -13.7% | 0.04% | +20.0% |
| Q2 2018 | $5,075,000 | -3.4% | 33,284 | -3.6% | 0.04% | -7.9% |
| Q1 2018 | $5,253,000 | +12.8% | 34,513 | +4.8% | 0.04% | +22.6% |
| Q4 2017 | $4,656,000 | +21.3% | 32,935 | +6.1% | 0.03% | +10.7% |
| Q3 2017 | $3,839,000 | +10.1% | 31,052 | +5.2% | 0.03% | +7.7% |
| Q2 2017 | $3,487,000 | +11.7% | 29,515 | +0.8% | 0.03% | +8.3% |
| Q1 2017 | $3,122,000 | +9.3% | 29,282 | +4.0% | 0.02% | +4.3% |
| Q4 2016 | $2,856,000 | -3.4% | 28,168 | +6.0% | 0.02% | -8.0% |
| Q3 2016 | $2,955,000 | +0.9% | 26,585 | +1.0% | 0.02% | 0.0% |
| Q2 2016 | $2,928,000 | +22.7% | 26,316 | +2.5% | 0.02% | +19.0% |
| Q1 2016 | $2,386,000 | +4.7% | 25,677 | -3.4% | 0.02% | -4.5% |
| Q4 2015 | $2,278,000 | -15.4% | 26,568 | -8.8% | 0.02% | -15.4% |
| Q3 2015 | $2,693,000 | -77.0% | 29,131 | -75.5% | 0.03% | -48.0% |
| Q2 2015 | $11,730,000 | +126.3% | 119,116 | +130.4% | 0.05% | +13.6% |
| Q1 2015 | $5,184,000 | – | 51,691 | – | 0.04% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Broadcrest Asset Management, LLC | 275,000 | $18,719,250 | 20.14% |
| Montanaro Asset Management Ltd | 408,800 | $27,827,016 | 4.90% |
| Sandhill Capital Partners LLC | 613,061 | $41,731,091 | 3.90% |
| Pembroke Management, LTD | 365,611 | $24,887,141 | 3.40% |
| DF DENT & CO INC | 3,349,047 | $227,969,648 | 3.34% |
| Brown Capital Management | 3,158,004 | $214,965,332 | 3.30% |
| Ownership Capital B.V. | 1,786,273 | $121,591,603 | 3.05% |
| STONE RUN CAPITAL, LLC | 86,335 | $5,876,823 | 2.88% |
| Jackson Square Partners, LLC | 1,260,547 | $85,805,434 | 2.87% |
| Summit Creek Advisors LLC | 284,681 | $19,378,236 | 2.64% |